Risks of Long-Term Depo Provera Use Beyond 2 Years

Bone Health Concerns

• The American College of Obstetricians and Gynecologists (ACOG) does not advise limiting Depo Provera use to 2 years or routinely monitoring bone density after this timeframe, as the benefits of preventing unwanted pregnancy generally outweigh the risks of bone density loss 1, 2
• Depo Provera causes reductions in bone mineral density (BMD), which prompted the FDA to issue a black box warning in 2004 1
• Subsequent research has shown substantial recovery of BMD after discontinuation of Depo Provera 1
• Despite these concerns, ACOG does not recommend limiting use to 2 years due to the risk of unwanted pregnancy if contraceptive options are limited 1

Menstrual Changes

• Nearly all patients experience menstrual irregularities initially, which typically improve over time 3, 1
• These menstrual changes are generally not harmful but may affect patient satisfaction and continuation rates 4

Weight Gain

• Weight gain is a common side effect with long-term use 3, 1
• Studies in both adolescents and adults suggest that weight gain status at 6 months is a strong predictor of future excessive weight gain with ongoing DMPA use 1
• Not all patients experience weight gain, but those who show early weight gain (>5% at 6 months) may experience significant increases in BMI with continued use 5

Return to Fertility

• Long-term DMPA use is associated with a delayed return to fertility, typically 9 to 18 months after discontinuation 5, 4
• This delay occurs while the endometrial lining returns to its pre-DMPA state and ovulatory function returns 4
• Both subcutaneous and intramuscular DMPA formulations show similar delays to fertility after injection 4

Other Potential Side Effects

• Headache, mastalgia (breast pain), hair loss, and changes in libido may occur with continued use 3, 1

Recommendations for Patients Using Depo Provera Long-Term

• All patients using DMPA beyond 2 years should be counseled about measures to promote skeletal health, including daily intake of 1300 mg of calcium and 600 IU of vitamin D, regular weight-bearing exercise, and smoking cessation 1, 2, 3
• Patients should be evaluated for other risk factors for osteoporosis when considering long-term use 1, 3

Clinical Considerations

• For patients with risk factors for osteoporosis, alternatives to DMPA may be preferable for long-term contraception 5, 4
• Counseling about potential side effects before initiation improves continuation rates 3, 1

Evidence‑Based Recommendations for Intramuscular Medroxyprogesterone Acetate (DMPA)

Bone‑Health Management for Long‑Term Users

• Recommend that patients using DMPA for more than two years engage in regular weight‑bearing exercise to help preserve bone mineral density. 6
• Advise smoking cessation to reduce additional risk to bone health in long‑term DMPA users. 6

Screening for Underlying Pathology

• Unscheduled vaginal bleeding in adolescents using DMPA may indicate a sexually transmitted infection; clinicians should offer appropriate STI testing. 7

Contraceptive Effectiveness

• The typical‑use failure rate of DMPA is approximately 6 %, while perfect‑use failure is about 0.2 %. 6, 7

Management of Menstrual Irregularities with Depo‑Provera

Counseling and Patient Education

• Clinicians should reassure patients that menstrual changes (irregular bleeding, spotting, or amenorrhea) are expected with Depo‑Provera and are generally not harmful, according to the CDC MMWR Recommendations and Reports (2024) 8.

Pharmacologic Intervention for Persistent Bleeding

• For patients who experience persistent irregular bleeding despite counseling, a short course of non‑steroidal anti‑inflammatory drugs (NSAIDs) for 5–7 days is recommended to reduce bleeding, as per the CDC MMWR Recommendations and Reports (2024) 8.

Consideration of Alternative Contraception

• If bleeding remains unacceptable after NSAID therapy, clinicians should discuss and offer alternative contraceptive methods to the patient, following guidance from the CDC MMWR Recommendations and Reports (2024) 8.

Recommendations for Special Populations Using Depo‑Provera

Identified Risk Factors for Long‑Term Depo‑Provera Use

• Patients who test positive for antiphospholipid antibodies should be considered for alternative long‑acting reversible contraception because prolonged Depo‑Provera may exacerbate thrombotic risk. 9
• Individuals with a pre‑existing high risk for osteoporosis (e.g., low baseline bone mineral density, family history of fractures) should be offered non‑hormonal or lower‑risk hormonal methods, as long‑term Depo‑Provera can further diminish bone density. 9
• Other recognized osteoporosis risk factors (such as chronic glucocorticoid use, smoking, or sedentary lifestyle) also warrant consideration of alternative contraceptive strategies. 9

Preferred Alternative Contraceptive Methods

• Highly effective long‑acting reversible contraceptives—including copper intrauterine devices, progestin‑releasing intrauterine systems, and subdermal implants—have typical-use failure rates of less than 1 % per year and are recommended for patients with the above risk factors. 9